Allergy Therapeutics (LON:AGY) Releases Quarterly Earnings Results
by Mitch Edgeman · The Markets DailyAllergy Therapeutics (LON:AGY – Get Free Report) released its earnings results on Tuesday. The company reported GBX (0.38) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.91% and a positive return on equity of 227.10%. The company had revenue of GBX 3,628 million during the quarter.
Allergy Therapeutics Price Performance
Shares of AGY stock remained flat at GBX 10.30 on Thursday. The stock had a trading volume of 71,346 shares, compared to its average volume of 280,355. The stock has a market cap of £652.25 million, a PE ratio of -12.26, a P/E/G ratio of -30.70 and a beta of 0.83. The company has a current ratio of 1.28, a quick ratio of 1.48 and a debt-to-equity ratio of -213.13. The stock’s fifty day moving average price is GBX 10.96 and its 200 day moving average price is GBX 10.04. Allergy Therapeutics has a 1-year low of GBX 5 and a 1-year high of GBX 12.10.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.